Shunjun Jiang

ORCID: 0000-0002-0356-1386
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Diagnosis and Treatment
  • Pleural and Pulmonary Diseases
  • Airway Management and Intubation Techniques
  • Respiratory Support and Mechanisms
  • Advanced Radiotherapy Techniques
  • Lung Cancer Treatments and Mutations
  • Urban Transport and Accessibility
  • Pituitary Gland Disorders and Treatments
  • Congenital Diaphragmatic Hernia Studies
  • Cancer, Stress, Anesthesia, and Immune Response
  • Cancer Cells and Metastasis
  • Respiratory and Cough-Related Research
  • Esophageal Cancer Research and Treatment
  • Gastric Cancer Management and Outcomes
  • Radiomics and Machine Learning in Medical Imaging
  • Brain Metastases and Treatment
  • Medicinal Plants and Bioactive Compounds
  • Microbial infections and disease research
  • Trauma Management and Diagnosis
  • Myasthenia Gravis and Thymoma
  • Inflammasome and immune disorders
  • Bacillus and Francisella bacterial research
  • FOXO transcription factor regulation
  • Actinomycetales infections and treatment
  • Yersinia bacterium, plague, ectoparasites research

Guangzhou Medical University
2010-2024

First Affiliated Hospital of Guangzhou Medical University
2017-2024

State Key Laboratory of Respiratory Disease
2019-2024

National Clinical Research Center for Digestive Diseases
2019

National Clinical Research
2019

Central South University
2019

Optimal treatment for resectable esophageal squamous cell carcinoma (ESCC) is controversial, especially in the context of potential benefit combining PD-1 blockade with neoadjuvant therapy. This phase 2 study aimed to assess camrelizumab plus chemotherapy this population. Patients (clinical stage II-IVA) received two cycles chemoimmunotherapy (NIC) (200 mg on day 1) nab-paclitaxel (260 mg/m2 total 1 and 8) cisplatin (75 days 1-3) each 21-day cycle. Surgery was performed approximately 6 weeks...

10.1002/ijc.33976 article EN International Journal of Cancer 2022-02-21

There is an unmet clinical need for accurate non-invasive tests to facilitate the early diagnosis of lung cancer. We propose a combined model clinical, imaging, and cell-free DNA methylation biomarkers that aims improve classification pulmonary nodules.We conducted prospective specimen collection retrospective masked evaluation study. recruited participants with solitary nodule sized 5-30 mm from 24 hospitals across 20 cities in China. Participants who were aged 18 years or older had been...

10.1016/s2589-7500(23)00125-5 article EN cc-by-nc-nd The Lancet Digital Health 2023-08-09

Abstract Background Anlotinib has been shown to prolong progression-free survival (PFS) and overall (OS) for non-small cell lung cancer (NSCLC). Herein we sought analyze the effect of anlotinib in managing brain metastases (BM) its brain-associated toxicities. Methods The PFS OS versus placebo those with without BM recorded at baseline were calculated compared respectively. Time progression (TTBP), a direct indicator intracranial control, was also between placebo. All calculations adjusted...

10.1634/theoncologist.2019-0838 article EN The Oncologist 2020-02-20

Background: Preoperative percutaneous computed tomography (CT)-guided localization of pulmonary nodules plays a pivotal role in the diagnosis and treatment early-stage lung cancer. However, conventional manual techniques have inherent limitations achieving high degree accuracy. Consequently, novel robotic-assisted navigation system was developed to attain precise small nodules. This study aims investigate accuracy safety this clinical applications. Methods: Patients with peripheral solitary...

10.21037/tlcr-23-493 article EN Translational Lung Cancer Research 2023-11-01

Spontaneous ventilation video-assisted thoracoscopic surgery (SV-VATS) exhibits dual intraoperative and postoperative advantages for patients with non-small cell lung cancer (NSCLC). However, there is a lack of data regarding its long-term survival superiority over the double-lumen intubated mechanical (MV-VATS) or thoracotomy.A retrospective study was conducted from 2011 to 2018 in First Affiliated Hospital Guangzhou Medical University among NSCLC who underwent SV-VATS MV-VATS. Patients...

10.21037/tlcr-21-629 article EN Translational Lung Cancer Research 2021-10-01

Abstract Background Stage III non-small cell lung cancer is a heterogeneous disease. Several international guidelines recommend neoadjuvant treatment before surgery; however, upfront surgery the preferred approach for technically resectable in East Asia. The aim of this retrospective study was to evaluate long-term outcomes curative-intent stage IIIA/B cancer. Methods Patients who underwent with cIIIA/B were identified. clinical and pathological variables survival evaluated. Results Overall,...

10.1093/bjsopen/zrae008 article EN cc-by BJS Open 2024-01-15

The goal of this study was to explore the feasibility and safety spontaneous ventilation video-assisted thoracoscopic surgery (SV-VATS) for non-small-cell lung cancer (NSCLC) patients with poor function. NSCLC function who underwent SV-VATS or mechanical VATS (MV-VATS) from 2011 2018 were analyzed. 1:2 Propensity score matching (PSM) applied, short- long-term outcomes between group MV-VATS compared. Anesthesia time (226.18 ± 64.89 min vs. 248.27 76.07 min; P = 0.03), operative (140.85 163.12...

10.3389/fsurg.2022.800082 article EN cc-by Frontiers in Surgery 2022-03-02

Robot-assisted surgery (RAS) systems have been developed but rarely applied to lung nodule localization. This study aimed assess the feasibility and safety of using a robot-assisted navigation system in percutaneous localization.A computed tomography (CT)-guided was used localize simulated peripheral swine through fluorescent agent injection. After localization, thoracoscopic wedge resection performed. The deviation between target point needle tip measured professional 3-dimensional (3D)...

10.21037/qims-23-716 article EN Quantitative Imaging in Medicine and Surgery 2023-11-24

Recent studies have illuminated that blocking Ca2+ influx into effector cells is an attractive therapeutic strategy for lung injury. We hypothesize T-type calcium channel may be a potential target acute injury (ALI). In this study, the pharmacological activity of mibefradil (a classical inhibitor) was assessed in mouse model lipopolysaccharide- (LPS-) induced ALI. LPS challenged mice, (20 and 40 mg/kg) dramatically decreased total cell number, as well productions TNF-α IL-6 bronchoalveolar...

10.1155/2020/3691701 article EN cc-by Mediators of Inflammation 2020-11-10

Thymomas and thymic carcinomas are rare aggressive tumors that usually detected in advanced stages. Surgery is the mainstay of treatment; however, role surgery disease controversial due to factors such as myasthenia gravis; thus, decisions about whether perform surgical interventions complex. Further studies need be conducted explore potential benefits treatment tumors. This study proposed a predictive decision score (SDS) model optimize patient prognosis by identifying patients likely...

10.21037/gs-2024-527 article EN Gland Surgery 2024-12-01

Background: Spontaneous ventilation VATS (SV-VATS) is reported to be associated with faster recovery and fewer complications than mechanical video-assisted thoracic surgery (MV-VATS). This study aimed evaluate the effect of SV-VATS for patients spontaneous pneumothorax.Methods: We performed a randomized controlled trial at 10 medical centers by recruiting primary pneumothorax undergoing MV-VATS. Participants were randomly assigned (1:1), receive non-intubated or intubated one lung The...

10.2139/ssrn.3471340 article EN SSRN Electronic Journal 2019-01-01

This study aimed to understand the influence of naïve T cells in cytokine-induced killer (CIK) cell immunotherapy. A total 68 patients with advanced solid tumors received activated autologous CIK weekly. Objective responses (complete or partial responses, CR/PR) were observed 11 (16.2%, 11/68), five lasting more than 8 months, and 16 SD (23.5%, 16/68). The absolute number CD4+ who achieved CR/PR was higher PD (CR/PR vs PD= 90 149 226 cells/μL), as CD8+ 47 60 103 cells/μL). Patients high...

10.22541/au.159969795.59090226 preprint EN Authorea (Authorea) 2020-09-10
Coming Soon ...